Skip to main content

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC

In brief

Sacituzumab tirumotecan combo extends lung cancer control to 15 months

In a phase 3 trial of 455 patients with PD-L1-negative advanced nonsquamous lung cancer, sacituzumab tirumotecan plus pembrolizumab extended median progression-free survival to 15 months, compared with 5.7 months with chemotherapy plus pembrolizumab. Severe adverse events were less common with the new combination, though mouth sores were frequent; overall survival results are still immature.

Journal
The New England journal of medicine (Q1)
Published
25 October 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, et al.
PMID
42929694
DOI
10.1056/NEJMoa2611280

Why clinicians should know about it

  • Picked for Oncology and Radiation Oncology (top studies of the week, 22 November 2026): Phase III randomized trial tests ADC-immunotherapy against standard first-line therapy

Abstract

BACKGROUND: Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain suboptimal. METHODS: In this phase 3, open-label, randomized trial, we evaluated sacituzumab tirumotecan plus pembrolizumab in patients with previously untreated locally advanced or metastatic nonsquamous NSCLC without targetable genomic alterations and a PD-L1 tumor proportion score of less than 1%. Patients were randomly assigned in a 1:1 ratio to receive sacituzumab tirumotecan plus pembrolizumab or chemotherapy plus pembrolizumab. The primary end point was progression-free survival as assessed by blinded independent central review. Overall survival was a secondary end point. This report presents the results of the prespecified interim analysis. RESULTS: A total of 455 patients were randomly assigned to receive sacituzumab tirumotecan plus pembrolizumab (229 patients) or chemotherapy plus pembrolizumab (226 patients). After a median follow-up of 9.7 months, the median progression-free survival was significantly longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 months vs. 5.7 months; hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.36 to 0.65; P<0.001). An objective response occurred in 50.2% and 47.3% of the patients, respectively, and the median duration of response was 13.6 months and 6.8 months. Overall survival data were immature; the hazard ratio for death was 0.58 (95% CI, 0.38 to 0.88). Adverse events of grade 3 or higher that occurred after the start of treatment were reported in 47.6% of the patients assigned to receive sacituzumab tirumotecan plus pembrolizumab and in 60.6% of those assigned to receive chemotherapy plus pembrolizumab. Stomatitis was common with sacituzumab tirumotecan plus pembrolizumab, but the events were predominantly grade 1 or 2. CONCLUSIONS: Among patients with PD-L1-negative advanced nonsquamous NSCLC without targetable genomic alterations, first-line treatment with sacituzumab tirumotecan plus pembrolizumab led to significantly longer progression-free survival than chemotherapy plus pembrolizumab. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung06 ClinicalTrials.gov number, NCT06711900.).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.